These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 38290907)

  • 21. Exenatide Delays Gastric Emptying in Patients with Type 2 Diabetes Mellitus but not in Those with Gastroparetic Conditions.
    Beti C; Stratmann B; Bokman G; Dreier J; Hauber M; Lee-Barkey YH; Fischer M; Knabbe C; Tschoepe D
    Horm Metab Res; 2019 Apr; 51(4):267-273. PubMed ID: 30690693
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gastrointestinal actions of glucagon-like peptide-1-based therapies: glycaemic control beyond the pancreas.
    Smits MM; Tonneijck L; Muskiet MH; Kramer MH; Cahen DL; van Raalte DH
    Diabetes Obes Metab; 2016 Mar; 18(3):224-35. PubMed ID: 26500045
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of the GLP-1 receptor agonist lixisenatide on postprandial glucose and gastric emptying--preclinical evidence.
    Werner U
    J Diabetes Complications; 2014; 28(1):110-4. PubMed ID: 23992745
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Short-acting glucagon-like peptide-1 receptor agonists as add-on to insulin therapy in type 1 diabetes: A review.
    Albèr A; Brønden A; Knop FK
    Diabetes Obes Metab; 2017 Jul; 19(7):915-925. PubMed ID: 28211611
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
    Nauck MA; Meier JJ; Cavender MA; Abd El Aziz M; Drucker DJ
    Circulation; 2017 Aug; 136(9):849-870. PubMed ID: 28847797
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical Consequences of Delayed Gastric Emptying With GLP-1 Receptor Agonists and Tirzepatide.
    Jalleh RJ; Plummer MP; Marathe CS; Umapathysivam MM; Quast DR; Rayner CK; Jones KL; Wu T; Horowitz M; Nauck MA
    J Clin Endocrinol Metab; 2024 Oct; ():. PubMed ID: 39418085
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Can GLP-1 preparations be used in children and adolescents with diabetes mellitus?
    Shehadeh N; Daich E; Zuckerman-Levin N
    Pediatr Endocrinol Rev; 2014 Mar; 11(3):324-7. PubMed ID: 24716398
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system.
    Vergès B; Bonnard C; Renard E
    Diabetes Metab; 2011 Dec; 37(6):477-88. PubMed ID: 21871831
    [TBL] [Abstract][Full Text] [Related]  

  • 29. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art.
    Nauck MA; Quast DR; Wefers J; Meier JJ
    Mol Metab; 2021 Apr; 46():101102. PubMed ID: 33068776
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis.
    Pinelli NR; Hurren KM
    Ann Pharmacother; 2011 Jul; 45(7-8):850-60. PubMed ID: 21730278
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The physiology of glucagon-like peptide-1 and its role in the pathophysiology of type 2 diabetes mellitus].
    Escalada FJ
    Med Clin (Barc); 2014 Sep; 143 Suppl 2():2-7. PubMed ID: 25437458
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Particulate Gastric Contents in Patients Prescribed Glucagon-Like Peptide 1 Receptor Agonists After Appropriate Perioperative Fasting: A Report of 2 Cases.
    Wilson PR; Bridges KH; Wilson SH
    A A Pract; 2023 Aug; 17(8):e01712. PubMed ID: 37616174
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of Lixisenatide Versus Liraglutide (Short- and Long-Acting GLP-1 Receptor Agonists) on Esophageal and Gastric Function in Patients With Type 2 Diabetes.
    Quast DR; Schenker N; Menge BA; Nauck MA; Kapitza C; Meier JJ
    Diabetes Care; 2020 Sep; 43(9):2137-2145. PubMed ID: 32647054
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The extra-pancreatic effects of GLP-1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems.
    Seufert J; Gallwitz B
    Diabetes Obes Metab; 2014 Aug; 16(8):673-88. PubMed ID: 24373150
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Glucagon-like Peptide-1 Receptor Agonists in the Management of Type 2 Diabetes Mellitus and Obesity: The Impact of Pharmacological Properties and Genetic Factors.
    Klen J; Dolžan V
    Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35408810
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Retained Gastric Contents After Adequate Fasting Associated with GLP-1 Receptor Agonist Use: A Report of 3 Cases.
    Kittner SL; Talbott AL; Vishneski SR; Narbaiza J; Shields JS
    JBJS Case Connect; 2023 Oct; 13(4):. PubMed ID: 37943967
    [TBL] [Abstract][Full Text] [Related]  

  • 37. alpha-Glucosidase inhibition (acarbose) fails to enhance secretion of glucagon-like peptide 1 (7-36 amide) and to delay gastric emptying in Type 2 diabetic patients.
    Hücking K; Kostic Z; Pox C; Ritzel R; Holst JJ; Schmiegel W; Nauck MA
    Diabet Med; 2005 Apr; 22(4):470-6. PubMed ID: 15787675
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.
    Neumiller JJ
    J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S16-29. PubMed ID: 19801361
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differential effects of GLP-1 receptor agonists on components of dysglycaemia in individuals with type 2 diabetes mellitus.
    Owens DR; Monnier L; Bolli GB
    Diabetes Metab; 2013 Dec; 39(6):485-96. PubMed ID: 24156868
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Low Incidence of Pulmonary Aspiration During Upper Endoscopy in Patients Prescribed a Glucagon-Like Peptide 1 Receptor Agonist.
    Anazco D; Fansa S; Hurtado MD; Camilleri M; Acosta A
    Clin Gastroenterol Hepatol; 2024 Jun; 22(6):1333-1335.e2. PubMed ID: 38043694
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.